Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · KOPRAN

KOPRAN LTD.

HealthcarePharmaceuticals & Biotechnology₹1282 cr market cap
₹266.74 ▲ +0.3% today As of 19 Nov 2026
52-week low ₹108.0452-week high ₹290.90

-8.6% from the 52-week high · +146.1% above the low

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.

The short version. KOPRAN LTD. reported revenue of ₹211 crore for Sep 2026, up 78.8% from a year earlier. Net profit was ₹4 crore. Return on equity was 4.9% in Mar 2026. Promoter holding was 41.82% in Sep 2026, down 2.64 points over 8 quarters.

1 · The price

How has the stock traded?

KOPRAN LTD. trades 8.6% below its 52-week high and 146.1% above its 52-week low.

Change over period: —

1M-4.4%
3M+28.2%
6M+59.1%
1Y+95.7%

2 · The business

Is it growing?

Sales, year on year+78.8%

Sep 2026 revenue of ₹211 cr.

Net margin2.1%

10.5 pts higher than a year earlier.

3-year growth-1.9% profit

Revenue compounded at 7.2% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue211154234194118135172166
Net profit47199-1071010
Net margin %2.14.48.14.8-8.45.55.66.3
EPS (₹)0.911.393.911.93-2.061.542.02.15

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue681630615551478492359358
Net profit2639512761622124
Net margin %3.86.18.34.912.812.55.86.7
EPS (₹)5.337.9810.575.6512.6614.244.865.55

3 · The quality

How well does it turn capital into profit?

Return on equity was 4.9% in Mar 2026; debt to equity is 0.29.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %4.97.410.46.2
Return on capital %8.010.414.58.9
EBITDA margin %9.112.114.19.9
Net margin %3.86.18.14.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR7.2%6.0%
Profit CAGR-1.9%-16.0%
Debt to equity0.29
Interest cover4.3x
Current ratio1.51
P/E ratio32.4

4 · The owners

Who holds it, and are they adding?

Promoter holding41.82%

Down 2.64 pts over 8 quarters.

Foreign institutions0.91%

Up 0.05 pts over 8 quarters.

Mutual fund schemes2

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter44.4644.4244.4244.4244.4244.4244.4241.82-2.64
FII0.861.120.760.60.360.570.510.91+0.05
DII000000000
Public54.6854.4554.8254.9855.2255.055.0657.27+2.59

Mutual fund holdings · Oct 2026

2 schemes hold this stock

2 the month before.

  • Motilal Oswal BSE Healthcare ETF0.04% of NAV
  • Bandhan BSE Healthcare Index Fund0.04% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for KOPRAN LTD. are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about KOPRAN LTD.

What is the KOPRAN LTD. share price?

KOPRAN LTD. (KOPRAN) last closed at ₹266.74, up 0.3% on the day. Its 52-week range is ₹108.04 to ₹290.90.

What is the market cap of KOPRAN LTD.?

KOPRAN LTD. has a market capitalisation of about ₹1,282 crore. Its price-to-earnings ratio is 32.4.

How are KOPRAN LTD.'s latest results?

KOPRAN LTD. reported revenue of ₹211 crore for Sep 2026, up 78.8% from a year earlier. Net profit was ₹4 crore. Return on equity was 4.9% in Mar 2026. Promoter holding was 41.82% in Sep 2026, down 2.64 points over 8 quarters.

Who owns KOPRAN LTD.?

As of Sep 2026, shareholding was: Promoter 41.82%, FII 0.91%, Public 57.27%.

How many mutual funds hold KOPRAN LTD.?

2 mutual fund schemes held KOPRAN LTD. in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 04 Sep 2025 · Final Dividend - Rs. 3
  • 02 Sep 2024 · Final Dividend - Rs. 3
  • 07 Sep 2023 · Dividend - Rs. 3
  • 04 Aug 2022 · Final Dividend - Rs. 3
  • 05 Aug 2021 · Final Dividend - Rs. 1.5
  • 05 Nov 2020 · Interim Dividend - Rs. 1.5

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.